Evidence map›Paper›PMID 33095405›Full record

ArticleCytotechnology2020

Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line.

Muhammed Sait Ertugrul, Hayrunnisa Nadaroglu, Ozge Balpinar Nalci, Ahmet Hacimuftuoglu, Azize Alayli

Open access · greenAbstract read
In one paragraph

Article in Cytotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Adult adrenal neuroblastoma: A case report.Molecular and clinical oncology · 2021
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Muhammed Sait ErtugrulDepartment of Pharmacology, Faculty of Pharmacy, Agri Ibrahim Cecen University, Agri, Turkey.
Hayrunnisa NadarogluDepartment of Food Technology, Vocational College of Technical Science, Ataturk University, 25240, Erzurum, Turkey. hnisa25@atauni.edu.tr.ORCID http://orcid.org/0000-0002-0536-4212
Ozge Balpinar NalciDepartment of Medical Pharmacology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey.
Ahmet HacimuftuogluDepartment of Medical Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey. ahmeth@atauni.edu.tr.
Azize AlayliDepartment of Nursing, Faculty of Health Sciences, Sakarya University of Applied Sciences, 54187, Sakarya, Turkey.
Atatürk University · TRAğrı İbrahim Çeçen University · TROndokuz Mayıs University · TRSakarya University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is one of the most widely seen under the age of 15 tumors that occur in the adrenal medulla and sympathetic ganglia. Cisplatin, an antineoplastic drug, is a Platinum-based compound and is known to inhibit the proliferation of neuroblastoma cells. Effective applications of nanoparticles in biomedical areas such as biomolecular, antimicrobial detection and diagnosis, tissue engineering, theranostics, biomarking, drug delivery, and anti-cancer have been investigated in many studies. This study aims to prepare the bioconjugates of CoS (cobalt sulfide) nanoparticles (NPs) with cisplatin combination groups and to evaluate their effects on the neuroblastoma cell line. Nanoparticle synthesis was done using the green synthesis technique using Punica granatum plant extract. The size and shape of CoS NPs were characterized by SEM, FT-IR, and XRD. Zeta potential was confirmed by the DLS study. For this purpose, the SH-SY5Y neuroblastoma cell line was cultured in a suitable cell culture medium. Cisplatin 5 µg and different concentrations (Cisplatin + CoS NPs bioconjugates (5, 10, 25, 50, 75 μg) doses were applied to SH-SY5Y neuroblastoma cell lines for 24 h. TAC, TOS and MTT tests were performed 24 h after the application. According to the MTT test results, cisplatin and CoS NP combinations reduced the proliferation of neuroblastoma cells by 78 to 57% compared to the cisplatin control. From the findings obtained; the most effective Bio-conjugate group was Cisplatin 5 μg/mL + CoS 75 μg/mL.

Indexed as

Bio-conjugateCisplatinCoS nanoparticlesSH-SY5Y neuroblastoma cell lines

Identifiers

PMID33095405
PMCPMC7695799
OpenAlexW3093771524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.